DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Mianserin is an investigational drug.
There have been 5 clinical trials for Mianserin. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Depression, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Forest Laboratories, Radboud University, and Mental Health Services in the Capital Region, Denmark.
There is one US patent protecting this investigational drug and sixteen international patents.
Recent Clinical Trials for Mianserin
|Treatment of Sleep Disturbances in Trauma-affected Refugees||Danish Center for Sleep Medicine||Phase 4|
|Treatment of Sleep Disturbances in Trauma-affected Refugees||Mental Health Services in the Capital Region, Denmark||Phase 4|
|Pharmacovigilance in Gerontopsychiatric Patients||Hannover Medical School||Phase 3|
Top disease conditions for Mianserin
Top clinical trial sponsors for Mianserin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Mianserin||Start Trial||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Start Trial|
|Mianserin||Start Trial||Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Mianserin||Start Trial||Compounds useful for the treatment of metabolic disorders and synthesis of the same||North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC)||Start Trial|
|Mianserin||Start Trial||Therapeutic compounds and methods of use thereof||GENENTECH, INC. (South San Francisco, CA) XENON PHARMACEUTICALS INC. (Burnaby, BC, CA)||Start Trial|
|Mianserin||Start Trial||Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators||Reset Therapeutics, Inc. (South San Francisco, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Mianserin||European Patent Office||2528893||2030-01-29||Start Trial|
|Mianserin||European Patent Office||3138838||2030-01-29||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|